COSCIENS Biopharma Inc - Company Profile
Powered by 
All the sales intelligence you need on COSCIENS Biopharma Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how COSCIENS Biopharma Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with COSCIENS Biopharma Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
COSCIENS Biopharma Inc (COSCIENS), formerly, Aeterna Zentaris Inc is a specialty biopharmaceutical company. It develops and commercializes pharmaceutical and diagnostic products, focusing on areas with significant unmet medical needs. The company’s lead product, macimorelin (Macrilen; Ghryvelin), is an oral test that is approved for diagnosing adult growth hormone deficiency. The company is advancing avenanthramides for potential use in treating inflammatory bowel syndrome, atherosclerosis, and colon cancer. COSCIENS’ oat beta glucan is recognized for cholesterol-lowering and glucose metabolism benefits. The company’s pipeline includes macimorelin for treating amyotrophic lateral sclerosis and diagnosing childhood-onset growth hormone deficiency. COSCIENS is headquartered in Toronto, Ontario, Canada.
Headquarters
Canada
Address
Suite 3000, 222 Bay Street, Toronto, Ontario, M5K1E7
Website
cosciensbio.com
Telephone
1 843 9003223
No of Employees
40
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CSCI (TSE)
Revenue (2024)
$9.6M
34.2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-339.3%
(2024 vs 2023)
Market Cap*
$2.8M
Net Profit Margin (2024)
XYZ
-227.3%
(2024 vs 2023)
* As of and is in US$
COSCIENS Biopharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Macimorelin: Adult Growth Hormone Deficiency |
| Oat Beta Glucan |
| Avenanthramides |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company, through its subsidiary Aeterna Zentaris GmbH, entered into a 10-year exclusive distribution agreement with Wuzhou Drug International Trading Limited to register, import and commercialize Macrilen (macimorelin). |
| 2024 | Corporate Changes/Expansions | In August, the company changed its name to COSCIENS Biopharma Inc. |
| 2024 | Acquisitions/Mergers/Takeovers | In June, the company merged with Ceapro Inc. |
Competitor Comparison
| Key Parameters | COSCIENS Biopharma Inc | Pfizer Inc | Symrise AG | Tate & Lyle PLC | Aprea Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | Canada | United States of America | Germany | United Kingdom | United States of America |
| City | Toronto | New York City | Holzminden | London | Doylestown |
| State/Province | Ontario | New York | Niedersachsen | - | Pennsylvania |
| No. of Employees | 40 | 81,000 | 12,984 | 4,971 | 8 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Peter H. Puccetti | Interim Chief Executive Officer; Chairman | Executive Board | 2025 | - |
| Giuliano La Fratta | Senior Vice President - Finance; Chief Financial Officer | Senior Management | 2022 | - |
| Michael Teifel | Chief Scientific Officer; Senior Vice President - Non-Clinical Development | Senior Management | - | - |
| Matthias Gerlach | Managing Director - Aeterna Zentaris GmbH; Senior Vice President - Aeterna Zentaris GmbH | Senior Management | 2024 | - |
| Michel Regnier | Managing Director - Edmonton; Senior Vice President - Edmonton | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer